HRP20220264T8 - Proces za pripremanje n-((1r,2s,sr)-5-(terc-butilamino)-2-((s)-3-(7-terc-butilpirazolo[1,5-a][1,3,5]triazin-4-ilamino)-2-oksopirolidin-1-il)cikloheksil)acetamida - Google Patents
Proces za pripremanje n-((1r,2s,sr)-5-(terc-butilamino)-2-((s)-3-(7-terc-butilpirazolo[1,5-a][1,3,5]triazin-4-ilamino)-2-oksopirolidin-1-il)cikloheksil)acetamidaInfo
- Publication number
- HRP20220264T8 HRP20220264T8 HRP20220264TT HRP20220264T HRP20220264T8 HR P20220264 T8 HRP20220264 T8 HR P20220264T8 HR P20220264T T HRP20220264T T HR P20220264TT HR P20220264 T HRP20220264 T HR P20220264T HR P20220264 T8 HRP20220264 T8 HR P20220264T8
- Authority
- HR
- Croatia
- Prior art keywords
- tert
- butylpyrazolo
- oxopyrrolidin
- triazin
- ylamino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C327/00—Thiocarboxylic acids
- C07C327/20—Esters of monothiocarboxylic acids
- C07C327/22—Esters of monothiocarboxylic acids having carbon atoms of esterified thiocarboxyl groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrrole Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762534908P | 2017-07-20 | 2017-07-20 | |
| EP18785785.9A EP3655395B1 (en) | 2017-07-20 | 2018-07-19 | Process for the preparation of n-((1r,2s,sr)-5-(tert-butylamino)-2-((s)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide |
| PCT/US2018/042797 WO2019018592A2 (en) | 2017-07-20 | 2018-07-19 | PROCESS FOR THE PREPARATION OF N- ((1R, 2S, 5R) -5- (TERT-BUTYLAMINO) -2 - ((S) -3- (7-TERT-BUTYLPYRAZOLO [1,5-A]] 1,3 , 5] triazin-4-ylamino) -2-oxopyrrolidin-1-yl) cyclohexyl) acetamide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20220264T1 HRP20220264T1 (hr) | 2022-05-13 |
| HRP20220264T8 true HRP20220264T8 (hr) | 2022-05-27 |
Family
ID=63834628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220264TT HRP20220264T8 (hr) | 2017-07-20 | 2018-07-19 | Proces za pripremanje n-((1r,2s,sr)-5-(terc-butilamino)-2-((s)-3-(7-terc-butilpirazolo[1,5-a][1,3,5]triazin-4-ilamino)-2-oksopirolidin-1-il)cikloheksil)acetamida |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US11254679B2 (hr) |
| EP (1) | EP3655395B1 (hr) |
| JP (1) | JP2020527576A (hr) |
| KR (1) | KR20200031656A (hr) |
| CN (1) | CN110933946A (hr) |
| AU (1) | AU2018304290B2 (hr) |
| BR (1) | BR112020000418A2 (hr) |
| CA (1) | CA3070423A1 (hr) |
| CY (1) | CY1125023T1 (hr) |
| DK (1) | DK3655395T3 (hr) |
| EA (1) | EA202090346A1 (hr) |
| ES (1) | ES2907640T3 (hr) |
| HR (1) | HRP20220264T8 (hr) |
| HU (1) | HUE058049T2 (hr) |
| IL (2) | IL293088A (hr) |
| LT (1) | LT3655395T (hr) |
| PL (1) | PL3655395T3 (hr) |
| PT (1) | PT3655395T (hr) |
| RS (1) | RS62941B1 (hr) |
| SG (1) | SG11202000441QA (hr) |
| SI (1) | SI3655395T1 (hr) |
| WO (1) | WO2019018592A2 (hr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020007526A (es) * | 2018-01-22 | 2020-09-09 | Bristol Myers Squibb Co | Composiciones y metodos para tratar el cancer. |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1646633B1 (en) * | 2003-05-30 | 2009-04-15 | Choongwae Pharma Corporation | Beta-strand mimetics |
| US7671062B2 (en) * | 2006-07-28 | 2010-03-02 | Bristol-Myers Squibb Company | Modulators of chemokine receptor activity, crystalline forms and process |
| US7629351B2 (en) * | 2006-07-28 | 2009-12-08 | Bristol-Myers Squibb Company | N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino) pyrrolidin-1-yl)cyclohexyl)acetamide and other modulators of chemokine receptor activity, crystalline forms and process |
| CN100593536C (zh) * | 2007-01-09 | 2010-03-10 | 吉尔生化（上海）有限公司 | 一种n-芴甲氧羰基-n-三苯甲基-d-谷氨酰胺的合成法 |
| US8383812B2 (en) * | 2009-10-13 | 2013-02-26 | Bristol-Myers Squibb Company | N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes |
| EP2813512B1 (en) * | 2011-12-28 | 2021-03-31 | Chugai Seiyaku Kabushiki Kaisha | Peptide-compound cyclization method |
-
2018
- 2018-07-19 BR BR112020000418-9A patent/BR112020000418A2/pt active Search and Examination
- 2018-07-19 HU HUE18785785A patent/HUE058049T2/hu unknown
- 2018-07-19 PT PT187857859T patent/PT3655395T/pt unknown
- 2018-07-19 US US16/631,915 patent/US11254679B2/en active Active
- 2018-07-19 CN CN201880046394.0A patent/CN110933946A/zh active Pending
- 2018-07-19 CA CA3070423A patent/CA3070423A1/en active Pending
- 2018-07-19 RS RS20220175A patent/RS62941B1/sr unknown
- 2018-07-19 IL IL293088A patent/IL293088A/en unknown
- 2018-07-19 AU AU2018304290A patent/AU2018304290B2/en not_active Ceased
- 2018-07-19 WO PCT/US2018/042797 patent/WO2019018592A2/en unknown
- 2018-07-19 EA EA202090346A patent/EA202090346A1/ru unknown
- 2018-07-19 SI SI201830566T patent/SI3655395T1/sl unknown
- 2018-07-19 KR KR1020207004510A patent/KR20200031656A/ko active IP Right Grant
- 2018-07-19 JP JP2020502357A patent/JP2020527576A/ja active Pending
- 2018-07-19 EP EP18785785.9A patent/EP3655395B1/en active Active
- 2018-07-19 SG SG11202000441QA patent/SG11202000441QA/en unknown
- 2018-07-19 HR HRP20220264TT patent/HRP20220264T8/hr unknown
- 2018-07-19 LT LTEPPCT/US2018/042797T patent/LT3655395T/lt unknown
- 2018-07-19 ES ES18785785T patent/ES2907640T3/es active Active
- 2018-07-19 DK DK18785785.9T patent/DK3655395T3/da active
- 2018-07-19 PL PL18785785T patent/PL3655395T3/pl unknown
-
2020
- 2020-01-14 IL IL272034A patent/IL272034B/en unknown
-
2022
- 2022-02-22 US US17/677,312 patent/US20220177482A1/en not_active Abandoned
- 2022-02-23 CY CY20221100161T patent/CY1125023T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUE058049T2 (hu) | 2022-06-28 |
| IL272034B (en) | 2022-06-01 |
| DK3655395T3 (da) | 2022-03-07 |
| RS62941B1 (sr) | 2022-03-31 |
| BR112020000418A2 (pt) | 2020-07-14 |
| SI3655395T1 (sl) | 2022-04-29 |
| EP3655395A2 (en) | 2020-05-27 |
| AU2018304290B2 (en) | 2022-11-17 |
| HRP20220264T1 (hr) | 2022-05-13 |
| EP3655395B1 (en) | 2021-12-01 |
| IL272034A (en) | 2020-03-31 |
| CY1125023T1 (el) | 2023-03-24 |
| AU2018304290A8 (en) | 2020-04-02 |
| ES2907640T3 (es) | 2022-04-25 |
| US20200223852A1 (en) | 2020-07-16 |
| CN110933946A (zh) | 2020-03-27 |
| JP2020527576A (ja) | 2020-09-10 |
| LT3655395T (lt) | 2022-03-10 |
| AU2018304290A1 (en) | 2020-03-05 |
| SG11202000441QA (en) | 2020-02-27 |
| KR20200031656A (ko) | 2020-03-24 |
| US20220177482A1 (en) | 2022-06-09 |
| EA202090346A1 (ru) | 2020-08-18 |
| IL293088A (en) | 2022-07-01 |
| WO2019018592A2 (en) | 2019-01-24 |
| WO2019018592A3 (en) | 2019-02-28 |
| PT3655395T (pt) | 2022-02-22 |
| PL3655395T3 (pl) | 2022-03-07 |
| US11254679B2 (en) | 2022-02-22 |
| CA3070423A1 (en) | 2019-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT3458456T (pt) | Preparação de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidino-1-carboxamida | |
| IL262003A (en) | Liquid formulations of (s)-n-(5-((r)-2-(5,2-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[5,1-a]pyrimidin-3-yl)-3 -Hydroxypyrrolidine-1-carboxamide | |
| IL290905B1 (en) | Crystal form of (s)–n-(5–)–2–(r))5,2-difluorophenyl)-pyrrolidine-1-yl)-pyrazolo[5,1-a]pyrimidine-3-yl)-3 -Hydroxypyrrolidine-1-carboxamide hydrogen sulfate | |
| WO2018042343A3 (en) | Compounds that inhibit 3c and 3cl proteases and methods of use thereof | |
| MA54847A (fr) | Forme crystalline d'un n-(pyrazol-4-yl)sulfonyl-6-(pyrazol-1-yl)-2-(pyrrolidin-1-yl)pyridine-3-carboxamide pour traiter la mucoviscidose | |
| SI3256109T1 (sl) | Farmacevtski sestavki, ki obsegajo N-(3,5-dimetoksifenil)-N'-(1-metiletil)-N-(3-(metil-1H-pirazol-4-il) kinoksalin-6-il)etan-1,2-diamin | |
| HUE050733T2 (hu) | Eljárás (2Z,5Z)-5-(3-klór-4-((R)-2,3-dihidroxipropoxi)benzilidén)-2-(pro-pilimino)-3-(O-tolil)tiazolidin-4-on elõállítására és ezen eljárásban alkalmazott köztitermék | |
| IL289885A (en) | History of n-((7,6,5,3,2,1-hexahydro-s-inden-4-yl)carbamoyl)-7,6,5,4-tetrahydrobenzofuran-2-sulfonamide and related compounds as nlpr3 modulators for the treatment of multiple sclerosis | |
| NZ630033A (en) | Crystalline forms of 1-(3-tert-butyl-1-p-tolyl-1h-pyrazol-5-yl)-3-(5-fluoro-2-(1-(2-hydroxyethyl)-indazol-5-yloxy)benzyl)urea hydrochloride | |
| HUE058049T2 (hu) | Eljárás N-((1R,2S,SR)-5-(terc-butilamino)-2-((S)-3-(7-terc-butilpirazolo[1,5-A][1,3,5] triazin-4-ilamino)-2-oxopirrolidin-1-il)ciklohexil)acetamid elõállítására | |
| IL311430A (en) | PROCESS FOR THE PREPARATION OF SAFINAMIDE | |
| EP3927689A4 (en) | PROCESSES FOR THE PREPARATION OF (3R,4R)-1-BENZYL-N,4-DIMETHYLPIPERIDINE-3-AMINE OR A SALT THEREOF AND PROCESSES FOR THE PREPARATION OF TOFACITINIB THEREFORE | |
| AU2017900496A0 (en) | Compounds for Enhancing the Permeation of Active Pharmaceutical Ingredients through Skin |